Get the Stockscreener App
3.38
12.29%
0.37
After Hours:
3.33
-0.05
-1.48%
Opus Genetics Inc stock is traded at $3.38, with a volume of 2.35M.
It is up +12.29% in the last 24 hours and up +75.13% over the past month.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
See More
Previous Close:
$3.01
Open:
$3.01
24h Volume:
2.35M
Relative Volume:
3.53
Market Cap:
$233.10M
Revenue:
$8.38M
Net Income/Loss:
$-27.19M
P/E Ratio:
-3.1009
EPS:
-1.09
Net Cash Flow:
$-13.59M
1W Performance:
+45.69%
1M Performance:
+75.13%
6M Performance:
+215.89%
1Y Performance:
+193.91%
1-Day Range:
$3.01
$3.385
1-Week Range:
$2.21
$3.385
52-Week Range:
$0.65
$3.385
Opus Genetics Inc Stock (IRD) Company Profile
Name
Opus Genetics Inc
Sector
Industry
Phone
248-681-9815
Address
8 DAVIS DRIVE, DURHAM
Compare IRD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
3.38 | 207.58M | 8.38M | -27.19M | -13.59M | -1.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.87 | 121.26B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.28 | 83.04B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
828.24 | 50.22B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.00 | 43.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
348.85 | 39.16B | 4.98B | 69.60M | 525.67M | 0.5198 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-20-26 | Initiated | BTIG Research | Buy |
| Dec-10-25 | Initiated | B. Riley Securities | Buy |
| Nov-25-25 | Initiated | Piper Sandler | Overweight |
| Oct-29-25 | Initiated | Wedbush | Outperform |
| Oct-16-25 | Initiated | Chardan Capital Markets | Buy |
| Apr-11-25 | Initiated | Craig Hallum | Buy |
| Nov-13-24 | Resumed | H.C. Wainwright | Buy |
View All
Opus Genetics Inc Stock (IRD) Latest News
Revenues Not Telling The Story For Opus Genetics, Inc. (NASDAQ:IRD) After Shares Rise 43% - simplywall.st
Aug Opening: Is Opus Genetics Inc a strong growth stock2025 Price Targets & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Opus Genetics, Inc. (NASDAQ:IRD) Short Interest Update - MarketBeat
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026 - GlobeNewswire
Why Opus Genetics Inc. (R3X1) stock could rally stronglyJuly 2025 Rallies & Weekly High Momentum Picks - mfd.ru
Opus Genetics' (IRD) "Buy" Rating Reiterated at BTIG Research - MarketBeat
Where Opus Genetics Stands With Analysts - Benzinga
Opus Genetics to begin MERTK gene therapy trial in Abu Dhabi - Investing.com India
Opus Genetics (IRD) Initiates Gene Therapy Trial for Eye Disorder - GuruFocus
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa - The Manila Times
Fundamentals Check: Is TrueCar Inc. a stock for growth or value investorsExit Point & Low Volatility Stock Recommendations - baoquankhu1.vn
Opus Genetics, Inc. (NASDAQ:IRD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Opus Genetics, Inc. (NASDAQ:IRD) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Take Profit: Is Opus Genetics Inc benefiting from innovation trendsJuly 2025 Outlook & AI Powered Market Trend Analysis - baoquankhu1.vn
BTIG Research Begins Coverage on Opus Genetics (NASDAQ:IRD) - Defense World
Opus Genetics (NASDAQ:IRD) Stock Rating Upgraded by BTIG Research - MarketBeat
BTIG Initiates Coverage of Opus Genetics (IRD) with Buy Recommendation - Nasdaq
Opus Genetics stock initiated with Buy rating at BTIG on retinal disease focus - Investing.com Canada
BTIG Initiates Coverage on Opus Genetics (IRD) with a Buy Rating - GuruFocus
Wall Street Zen Upgrades Opus Genetics (NASDAQ:IRD) to Hold - MarketBeat
JPM26: Opus Genetics builds momentum in rare retinal gene therapy - Yahoo Finance
Opus Genetics, Inc. Announces Presentation at J.P. Morgan Healthcare Conference - TradingView
Virtual Reality Endpoints Improve Measurement Of Patients' Real-World Benefit - Clinical Leader
Opus Genetics highlights 2025 progress, upcoming 2026 catalysts - Yahoo Finance
How Opus Genetics Inc. stock reacts to oil pricesWeekly Profit Report & Risk Controlled Daily Trade Plans - Улправда
Merger Talk: How cyclical is Opus Genetics Inc. (R3X1) stock compared to rivalsTrade Risk Summary & Free Accurate Trade Setup Notifications - Улправда
How cyclical is Opus Genetics Inc. (R3X1) stock compared to rivals2025 Momentum Check & Community Verified Watchlist Alerts - Улправда
Earnings Risk: Is Opus Genetics Inc. stock attractive for growth ETFsPortfolio Performance Summary & Free Community Supported Trade Ideas - Улправда
How interest rate cuts could boost Opus Genetics Inc. stock2025 Major Catalysts & Weekly Stock Performance Updates - Улправда
Opus Genetics (IRD) Advances Clinical Trials and Regulatory Fili - GuruFocus
Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts - The Manila Times
Opus Genetics Details 2025 Progress and 2026 Milestones - TipRanks
Opus Genetics Highlights 2025 Progress and 2026 Catalysts - TradingView — Track All Markets
Opus Genetics (NASDAQ:IRD) Cut to Sell at Wall Street Zen - Defense World
Independent Chairman of Opus Genetics Picks Up 9.5% More Stock - simplywall.st
Caprolactam Chemicals Limited Stock Analysis Technical Signals for YEAR - earlytimes.in
What drives Opus Genetics Inc stock priceEx-Dividend Date Alerts & Small Investment Portfolio - earlytimes.in
Hedge Fund and Insider Trading News: Ken Griffin, Warren Buffett, Bridgewater Associates, AQR Capital Management, Schonfeld Strategic Advisors, D.E. Shaw, Millennium Management, Elliott Management, Discovery Capital Management, Opus Genetics Inc - Insider Monkey
Opus Genetics Advances Gene Therapy for Retinal Degeneration: A Study Update - MSN
Portfolio Shifts: How Opus Genetics Inc stock performs in stagflationWeekly Market Outlook & Low Risk High Reward Trade Ideas - moha.gov.vn
Opus Genetics (NASDAQ:IRD) Director Cam Gallagher Purchases 83,000 Shares - MarketBeat
Shorts Report: Why Opus Genetics Inc R3X1 stock is upgraded to buy - moha.gov.vn
B Riley Securities initiates coverage of Opus Genetics (IRD) with buy recommendation - MSN
Opus Genetics, Inc. (NASDAQ:IRD) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Soaring Eagle Acquisition Corp Equity Warrant Stock Analysis and ForecastLong-Term Growth Stocks & Superior Capital Appreciation - earlytimes.in
Opus Genetics Inc R3X1 Stock Analysis and ForecastMarket Insider Reports & Discover Strategies with Fellow Traders - earlytimes.in
MACD Signals Flash Warning for Compucom Software Limited StockMACD Trading Signals & Minimal Investment Big Returns - earlytimes.in
Opus Genetics rises as eye disease study to proceed without changes - MSN
Rate Hike: Why Opus Genetics Inc stock could benefit from AI revolutionInsider Selling & Proven Capital Preservation Tips - moha.gov.vn
Will Opus Genetics Inc. stock outperform growth indexesProfit Target & Consistent Growth Equity Picks - Улправда
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Opus Genetics Inc Stock (IRD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Opus Genetics Inc Stock (IRD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gallagher Cam | Director |
Dec 29 '25 |
Buy |
1.98 |
81,000 |
160,275 |
1,891,430 |
| Foundation Fighting Blindness | Director |
Dec 09 '25 |
Sale |
2.15 |
4,000,000 |
8,600,000 |
5,492,171 |
0.10%
7.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):